Caris Life Sciences (CAI) Revenue (2024 - 2026)

Caris Life Sciences' Revenue history runs 3 years deep, the most recent figure standing at $216.2 million for Q1 2026.

• On a quarterly basis, Revenue rose 78.78% year-over-year to $216.2 million in Q1 2026; TTM through Mar 2026 was $907.3 million, a 100.51% increase from a year earlier, with the FY2025 full-year figure at $812.0 million, up 96.97% from the prior year.
• Revenue eased to $216.2 million in Q1 2026 per CAI's latest filing, from $292.9 million in the prior quarter.
• Across five years, Revenue topped out at $292.9 million in Q4 2025 and bottomed at $100.0 million in Q2 2024.
• The 3-year median for Revenue is $155.7 million (2024), against an average of $170.0 million.
• Across the five-year window, Revenue surged 125.44% in 2025 and soared 78.78% in 2026, its largest moves.
• Year by year, Revenue stood at $129.9 million in 2024, then surged by 125.44% to $292.9 million in 2025, then dropped by 26.19% to $216.2 million in 2026.
• Per Business Quant, the three latest CAI Revenue figures stand at $216.2 million (Q1 2026), $292.9 million (Q4 2025), and $216.8 million (Q3 2025).